DI-Leu16-IL2

Developed for: B-cell non-Hodgkin lymphoma · anaplastic large cell lymphoma · grade III lymphomatoid granulomatosis · intraocular lymphoma · MALT lymphoma · nodal marginal zone B-cell lymphoma · primary cutaneous B-cell lymphoma · small intestine lymphoma
+3 more
· splenic marginal zone lymphoma · testicular lymphoma · Waldenstrom macroglobulinemia
Investigated by: Alopexx Oncology, LLC · City of Hope Medical Center · National Cancer Institute (NCI)

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT00720135	Jan 2008 → Jul 2014	MALT lymphoma, Waldenstrom macroglobulinemia, anaplastic large cell lymphoma, grade III lymphomatoid granulomatosis +6	City of Hope Medical Center	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02151903	Nov 2014 → Jul 2016	B-cell non-Hodgkin lymphoma	Alopexx Oncology, LLC	Terminated	No outcome recorded
Phase 1/2	NCT01874288	Nov 2013 → Jan 2014	B-cell non-Hodgkin lymphoma	Alopexx Oncology, LLC	Terminated	No outcome recorded Stop: Enrollment

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	DI-Leu16-IL2	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00720135 ↗ 2 NCT01874288 ↗ NCT02151903 ↗
Known as	de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2	“de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2” NCT00720135 ↗
Known as	Di-leu16-il2 immunocytokine	ChEMBL registry synonym — accepted as the source's own label CHEMBL4650391 ↗
Modality	Protein / enzyme biologic	“fusion protein cytokine therapy” NCT00720135 ↗
Route	Intravenous	“Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours” NCT00720135 ↗